From the FDA Drug Label
The recommended dosage of ANORO ELLIPTA for maintenance treatment of COPD is 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of ANORO ELLIPTA 62.5/25 mcg) once daily by oral inhalation. The current recommended dose of Anoro (vilanterol and umeclidinium) for chronic obstructive pulmonary disease (COPD) is:
- 62.5 mcg umeclidinium and
- 25 mcg vilanterol once daily by oral inhalation 1. Key points:
- Use at the same time every day
- Do not use more than 1 time every 24 hours
- No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment 1.
From the Research
The recommended dose of Anoro (umeclidinium/vilanterol) for chronic obstructive pulmonary disease (COPD) is one inhalation once daily, delivering 62.5 micrograms of umeclidinium and 25 micrograms of vilanterol. This medication should be taken at the same time each day to maintain consistent blood levels and maximize effectiveness. Anoro comes as a dry powder inhaler called Ellipta, which should be used according to the proper inhalation technique - a steady, deep breath followed by holding the breath for about 3-4 seconds. Patients should not exhale into the device, and the protective cover should only be opened when ready to take a dose.
Key Points to Consider
- The dual bronchodilator approach of umeclidinium and vilanterol provides more effective symptom relief than either component alone for patients with moderate to severe COPD 2.
- Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine receptors to prevent airway constriction, while vilanterol is a long-acting beta-2 agonist (LABA) that stimulates receptors to relax airway smooth muscle.
- Clinical data published on the combination of umeclidinium/vilanterol in patients with COPD have shown greater improvements in lung function compared to monotherapies 3, 4.
- The most recent and highest quality study, a systematic review published in 2019, confirms the efficacy and safety of once-daily umeclidinium/vilanterol (62.5 mcg/25 mcg) in COPD patients 2.
Administration and Usage
- Patients should use the Ellipta inhaler correctly to ensure optimal delivery of the medication.
- The medication should be taken at the same time each day to maintain consistent blood levels and maximize effectiveness.
- Patients should not exhale into the device, and the protective cover should only be opened when ready to take a dose.